SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Says GlaxoSmithKline Drug Promacta Fails to Control Bleeding

May 29, 2008 | 
1 min read

WASHINGTON - An experimental drug from GlaxoSmithKline does not significantly lower bleeding in patients with a rare blood disorder, according to the Food and Drug Administration.

Regulatory
GlaxoSmithKline Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Robert F Kennedy Jr speaking at the White House
Government
Calls To End Kennedy’s Leadership Follow Marks’ Abrupt Exit
April 1, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA
Marks’ Sudden Departure From FDA Magnifies Uncertainty, Sends Biopharma Shares Down
March 31, 2025
 · 
3 min read
 · 
Heather McKenzie
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Amgen, Aldeyra and Argenx
March 31, 2025
 · 
3 min read
 · 
Tristan Manalac
Wooden blocks with arrow and error icon. Delays and disruptions, stop the process, critical error concept
Alzheimer’s disease
EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi
March 28, 2025
 · 
2 min read
 · 
Dan Samorodnitsky